News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,425 Results
Type
Article (23233)
Company Profile (110)
Press Release (240077)
Multimedia
Podcasts (50)
Webinars (4)
Section
Business (66559)
Career Advice (216)
Deals (11340)
Drug Delivery (37)
Drug Development (47735)
Employer Resources (19)
FDA (6348)
Job Trends (5028)
News (129357)
Policy (10569)
Tag
Academia (1329)
Academic (1)
Accelerated approval (10)
Adcomms (15)
Allergies (38)
Alliances (21906)
ALS (86)
Alzheimer's disease (728)
Antibody-drug conjugate (ADC) (204)
Approvals (6444)
Artificial intelligence (138)
Autoimmune disease (56)
Automation (14)
Bankruptcy (57)
Best Places to Work (4422)
BIOSECURE Act (6)
Biosimilars (102)
Biotechnology (91)
Bladder cancer (93)
Brain cancer (38)
Breast cancer (316)
Cancer (3039)
Cardiovascular disease (101)
Career advice (184)
Career pathing (6)
CAR-T (237)
CDC (4)
Cell therapy (661)
Cervical cancer (21)
Clinical research (38923)
Collaboration (742)
Company closure (3)
Compensation (236)
Complete response letters (24)
COVID-19 (1288)
CRISPR (62)
C-suite (243)
Cystic fibrosis (82)
Data (2744)
Denatured (9)
Depression (25)
Diabetes (155)
Diagnostics (2308)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (102)
Drug pricing (28)
Drug shortages (2)
Duchenne muscular dystrophy (104)
Earnings (24302)
Editorial (9)
Employer branding (2)
Employer resources (19)
Events (38996)
Executive appointments (347)
FDA (7488)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (5)
Frontotemporal dementia (7)
Funding (523)
Gene editing (122)
Generative AI (8)
Gene therapy (398)
GLP-1 (265)
Government (1252)
Grass and pollen (2)
Guidances (121)
Healthcare (6139)
HIV (16)
Huntington's disease (15)
IgA nephropathy (38)
Immunology and inflammation (123)
Immuno-oncology (14)
Indications (36)
Infectious disease (1368)
Inflammatory bowel disease (91)
Inflation Reduction Act (5)
Influenza (36)
Intellectual property (82)
Interviews (45)
IPO (5244)
IRA (6)
Job creations (826)
Job search strategy (153)
Kidney cancer (16)
Labor market (9)
Layoffs (194)
Leadership (3)
Legal (1757)
Liver cancer (66)
Longevity (8)
Lung cancer (539)
Lymphoma (256)
Machine learning (16)
Management (5)
Manufacturing (293)
MASH (39)
Medical device (2479)
Medtech (2488)
Mergers & acquisitions (6490)
Metabolic disorders (315)
Multiple sclerosis (93)
NASH (4)
Neurodegenerative disease (101)
Neuropsychiatric disorders (10)
Neuroscience (1185)
NextGen: Class of 2025 (1740)
Non-profit (996)
Now hiring (10)
Obesity (117)
Opinion (78)
Ovarian cancer (114)
Pain (34)
Pancreatic cancer (108)
Parkinson's disease (124)
Partnered (13)
Patents (172)
Patient recruitment (168)
Peanut (15)
People (18545)
Pharmaceutical (17)
Pharmacy benefit managers (2)
Phase I (14203)
Phase II (17631)
Phase III (11780)
Pipeline (1401)
Policy (49)
Postmarket research (926)
Preclinical (6504)
Press Release (57)
Prostate cancer (119)
Psychedelics (13)
Radiopharmaceuticals (136)
Rare diseases (368)
Real estate (1792)
Recruiting (8)
Regulatory (9212)
Reports (20)
Research institute (1316)
Resumes & cover letters (33)
Rett syndrome (10)
RNA editing (7)
RSV (19)
Schizophrenia (36)
Series A (89)
Series B (62)
Service/supplier (3)
Sickle cell disease (81)
Special edition (7)
Spinal muscular atrophy (106)
Sponsored (17)
Startups (1556)
State (1)
Stomach cancer (13)
Supply chain (26)
Tariffs (12)
The Weekly (40)
Vaccines (385)
Venture capital (26)
Weight loss (48)
Women's health (13)
Worklife (2)
Date
Today (68)
Last 7 days (394)
Last 30 days (1219)
Last 365 days (14316)
2025 (11310)
2024 (16445)
2023 (18542)
2022 (24788)
2021 (25064)
2020 (21737)
2019 (15147)
2018 (11481)
2017 (12932)
2016 (11807)
2015 (14333)
2014 (10156)
2013 (8429)
2012 (8662)
2011 (8728)
2010 (7711)
Location
Africa (210)
Alabama (20)
Alaska (3)
Arizona (53)
Arkansas (2)
Asia (30678)
Australia (4414)
California (4003)
Canada (1123)
China (642)
Colorado (112)
Connecticut (117)
Delaware (132)
Europe (40663)
Florida (436)
Georgia (93)
Hawaii (1)
Idaho (21)
Illinois (217)
India (30)
Indiana (74)
Iowa (11)
Japan (248)
Kansas (24)
Kentucky (7)
Louisiana (3)
Maine (52)
Maryland (531)
Massachusetts (3295)
Michigan (57)
Minnesota (142)
Mississippi (1)
Missouri (22)
Montana (9)
Nebraska (7)
Nevada (36)
New Hampshire (11)
New Jersey (1241)
New Mexico (15)
New York (1218)
North Carolina (451)
North Dakota (9)
Northern California (1884)
Ohio (115)
Oklahoma (8)
Oregon (8)
Pennsylvania (813)
Puerto Rico (4)
Rhode Island (19)
South America (297)
South Carolina (1)
Southern California (1536)
Tennessee (29)
Texas (730)
United States (14352)
Utah (106)
Virginia (111)
Washington D.C. (16)
Washington State (461)
Wisconsin (30)
263,425 Results for "gamida cell ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.
March 27, 2024
·
5 min read
Business
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
Gamida Cell Ltd. today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.
March 22, 2024
·
1 min read
Business
Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management
Gamida Cell today announced new executive leadership following a successful restructuring transaction (“Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024.
June 18, 2024
·
4 min read
Business
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
March 27, 2024
·
15 min read
Genetown
Gamida Cell Actively Pursuing Strategic Alternatives - Jan 29, 2024
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction.
January 29, 2024
·
2 min read
Genetown
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Gamida Cell Ltd. today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings.
January 17, 2024
·
11 min read
Press Releases
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
October 23, 2025
·
9 min read
Genetown
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Gamida Cell Ltd. presented data highlighting its expanded access program for FDA-approved allogeneic stem cell therapy Omisirge® and Phase 1 data for its allogeneic cryopreserved natural killer cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.
February 23, 2024
·
13 min read
Business
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
Gamida Cell Ltd today reported financial results for the quarter ended September 30, 2023, and provided a business update.
November 14, 2023
·
17 min read
Genetown
First Patient Receives Gamida Cell’s Omisirge™ (omidubicel-onlv)
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the first patient has received a stem cell transplant with Omisirge.
September 27, 2023
·
11 min read
1 of 26,343
Next
